Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
NRG Oncology
M.D. Anderson Cancer Center
Novartis
Pfizer
Institut Cancerologie de l'Ouest
Obsidian Therapeutics, Inc.
University of Zurich
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Mayo Clinic
M.D. Anderson Cancer Center
Filamon LTD
Fred Hutchinson Cancer Center
Mayo Clinic
University of California, Davis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ViroMissile, Inc.
Replimune Inc.
University of Florida
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
Essen Biotech
OHSU Knight Cancer Institute
Daiichi Sankyo
M.D. Anderson Cancer Center
Second Life Therapeutics
AgonOx, Inc.
Novartis
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Inhibrx Biosciences, Inc
Degron Therapeutics Co.
University Health Network, Toronto
The First Affiliated Hospital of Xinxiang Medical College
Cancer Research UK
Petrov, Andrey
AstraZeneca
Revolution Medicines, Inc.
Tempus AI
Virginia Commonwealth University
Hadassah Medical Organization
British Columbia Cancer Agency
Guangzhou FineImmune Biotechnology Co., LTD.
Washington University School of Medicine